JUL 11, 2022 3:00 AM PDT

Boosting CAR T Cell Therapy with TIGIT Blockade

WRITTEN BY: Katie Kokolus

Chimeric antigen receptor (CAR) T Cell therapy has emerged as a promising immunotherapeutic approach to treat blood cancers, even leading to long-lasting remission for some advanced cases.  The FDA has approved six CAR T Cell therapies to treat some forms of lymphoma, leukemia, and multiple myeloma. 

T cells, a component of the immune system, carry out the cytotoxic mechanisms of the anti-tumor immune response, which means that they seek out, attack, and kill cancer cells.  T cell receptors (TCR) recognize proteins, called antigens , on the surface of cancer cells, and this recognition activates anti-cancer immune pathways.  Tumors can evade the immune system when TCRs do not adequately recognize antigens on cancer cells. 

CAR T cell therapies consist of specially engineered T cells programmed to recognize cancer and promote immune activation and subsequent cancer cell death.  To generate CAR T cells, doctors harvest a patient’s T cells by drawing blood.  Then, specialized technicians modify the T cells in a laboratory, resulting in a TCR primed to recognize the patient’s cancer.  The CAR T cells are then expanded so that doctors can return large numbers of highly effective immune cells to the patient. 

Source: The National Cancer Institute

While CAR T cell methodology has led to cures in hard-to-treat cancers, only about half, or fewer, patients treated with CAR T cells experience long-term remission.  Thus, identifying mechanisms behind the relapse of CAR T cell-treated cancers is a high priority among cancer researchers.  A study published in Cancer Discovery has uncovered a potential explanation for the reduced remission rates seen in CAR T cell-treated non-Hodgkin lymphoma (NHL). 

One CAR T cell modality used to treat NHL targets CD19, a protein present on lymphoma cells.  This treatment is effective in less than 40% of patients.  The researchers investigated the genetic landscape of CAR T cells following infusion.  Patients provided pre- and post-infusion samples, which researchers analyzed using single-cell sequencing.  The study included 17 patients, 13 responded favorably, and four responded poorly.

The researchers found that non-responding patients exhibited a different exhaustion profile than those who responded.  They identified one marker significantly associated with poor CAR T cell response: TIGIT (which stands for “T cell immunoreceptor with immunoglobulin and ITIM domain”).  The association between poor response and TIGIT suggests it is a viable target for cancer immunotherapy. 

The study also included a pre-clinical component where a mouse model of human NHL was used to assess the potential impact of TIGIT blockade.  The researchers found that blocking TIGIT, in combination with CAR T cells, improved the efficacy of the CAR T cell treatment. 

 

Sources: Nature, Blood Advances, Cancer Discovery, Curr Opinions Oncol, JITC, NCI Visuals Online

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
MAY 02, 2022
Cancer
Prostate Cancer: What's in a Name?
MAY 02, 2022
Prostate Cancer: What's in a Name?
Hearing the word “cancer” could have a significant psychological impact on a patient waiting on a diagnosis. ...
JUN 27, 2022
Cancer
A Genomic Scan Detects Cancer-Driving Mutations
JUN 27, 2022
A Genomic Scan Detects Cancer-Driving Mutations
Cancer develops when the DNA in our cells becomes altered, resulting in a gene mutation.  DNA alterations can occur ...
JUL 14, 2022
Cancer
Acupuncture Can Help Control Cancer-Related Pain
JUL 14, 2022
Acupuncture Can Help Control Cancer-Related Pain
Acupuncture is a traditional Chinese medicine (TCM) technique aiming to stimulate specific points in the body.  In ...
AUG 04, 2022
Cancer
Fiber in Green Bananas Protects from Some Cancers
AUG 04, 2022
Fiber in Green Bananas Protects from Some Cancers
Starch, a natural, sugar-containing component in many green plants, is present in high concentrations in foods such as p ...
AUG 22, 2022
Immunology
A Lifetime of Mutations is Seen in Aging Immune Cells
AUG 22, 2022
A Lifetime of Mutations is Seen in Aging Immune Cells
Researchers have used advanced sequencing techniques to analyze immune cells in great detail. This work has shown that o ...
SEP 15, 2022
Cancer
Early-Onset Cancers are Rising: Do We Know Why?
SEP 15, 2022
Early-Onset Cancers are Rising: Do We Know Why?
Early-onset cancers, typically defined as those diagnosed in people aged approximately 20 - 50, have continually increas ...
Loading Comments...